Outcomes of relapse in patients with deferred autologous stem cell transplant after achieving at least very good partial response following bortezomib, adriamycin, dexamethasone chemotherapy for newly diagnosed multiple myeloma in the phase II PADIMAC trial
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2022 |
---|---|
Erschienen: |
2022 |
Enthalten in: |
Zur Gesamtaufnahme - volume:196 |
---|---|
Enthalten in: |
British journal of haematology - 196(2022), 4 vom: 01. Feb., Seite e33-e37 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Chan, Wei Yee [VerfasserIn] |
---|
Links: |
---|
Anmerkungen: |
Date Completed 01.03.2022 Date Revised 01.03.2022 published: Print-Electronic Citation Status MEDLINE |
---|
doi: |
10.1111/bjh.17903 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM331769107 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM331769107 | ||
003 | DE-627 | ||
005 | 20231225214206.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2022 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1111/bjh.17903 |2 doi | |
028 | 5 | 2 | |a pubmed24n1105.xml |
035 | |a (DE-627)NLM331769107 | ||
035 | |a (NLM)34636043 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Chan, Wei Yee |e verfasserin |4 aut | |
245 | 1 | 0 | |a Outcomes of relapse in patients with deferred autologous stem cell transplant after achieving at least very good partial response following bortezomib, adriamycin, dexamethasone chemotherapy for newly diagnosed multiple myeloma in the phase II PADIMAC trial |
264 | 1 | |c 2022 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 01.03.2022 | ||
500 | |a Date Revised 01.03.2022 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status MEDLINE | ||
650 | 4 | |a Clinical Trial, Phase II | |
650 | 4 | |a Letter | |
650 | 4 | |a Research Support, Non-U.S. Gov't | |
650 | 4 | |a autologous stem cell transplantation | |
650 | 4 | |a high dose therapy | |
650 | 4 | |a multiple myeloma | |
650 | 4 | |a myeloma therapy | |
650 | 7 | |a Bortezomib |2 NLM | |
650 | 7 | |a 69G8BD63PP |2 NLM | |
650 | 7 | |a Dexamethasone |2 NLM | |
650 | 7 | |a 7S5I7G3JQL |2 NLM | |
650 | 7 | |a Doxorubicin |2 NLM | |
650 | 7 | |a 80168379AG |2 NLM | |
700 | 1 | |a Counsell, Nicholas |e verfasserin |4 aut | |
700 | 1 | |a de Tute, Ruth |e verfasserin |4 aut | |
700 | 1 | |a De-Silva, Dunnya |e verfasserin |4 aut | |
700 | 1 | |a Phillips, Elizabeth H |e verfasserin |4 aut | |
700 | 1 | |a Cavenagh, Jamie |e verfasserin |4 aut | |
700 | 1 | |a Adedayo, Toyin |e verfasserin |4 aut | |
700 | 1 | |a Braganca, Nivette |e verfasserin |4 aut | |
700 | 1 | |a Roddie, Claire |e verfasserin |4 aut | |
700 | 1 | |a Streetly, Matthew |e verfasserin |4 aut | |
700 | 1 | |a Schey, Stephen |e verfasserin |4 aut | |
700 | 1 | |a Koh, Mickey B C |e verfasserin |4 aut | |
700 | 1 | |a Crowe, Josephine |e verfasserin |4 aut | |
700 | 1 | |a Morris, Treen C |e verfasserin |4 aut | |
700 | 1 | |a Cook, Gordon |e verfasserin |4 aut | |
700 | 1 | |a Clifton-Hadley, Laura |e verfasserin |4 aut | |
700 | 1 | |a Rabin, Neil |e verfasserin |4 aut | |
700 | 1 | |a Owen, Roger G |e verfasserin |4 aut | |
700 | 1 | |a Popat, Rakesh |e verfasserin |4 aut | |
700 | 1 | |a Yong, Kwee L |e verfasserin |4 aut | |
700 | 0 | |a PADIMAC investigators |e verfasserin |4 aut | |
700 | 1 | |a D'Sa, Shirley |e investigator |4 oth | |
700 | 1 | |a Virchis, Andres |e investigator |4 oth | |
700 | 1 | |a Quinn, Michael |e investigator |4 oth | |
700 | 1 | |a Crawley, Charles |e investigator |4 oth | |
700 | 1 | |a Pratt, Guy |e investigator |4 oth | |
700 | 1 | |a Cook, Mark |e investigator |4 oth | |
773 | 0 | 8 | |i Enthalten in |t British journal of haematology |d 1955 |g 196(2022), 4 vom: 01. Feb., Seite e33-e37 |w (DE-627)NLM000000396 |x 1365-2141 |7 nnns |
773 | 1 | 8 | |g volume:196 |g year:2022 |g number:4 |g day:01 |g month:02 |g pages:e33-e37 |
856 | 4 | 0 | |u http://dx.doi.org/10.1111/bjh.17903 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 196 |j 2022 |e 4 |b 01 |c 02 |h e33-e37 |